Cefdinir NDC 50090-3725

NDC codes

FDA NDC Directory

Product NDC (as listed)50090-3725Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50090-3725Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
50090-3725-0	50090372500	60 mL in 1 BOTTLE (50090-3725-0)Marketed from Oct 25, 2018

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Cefdinir
Generic name (nonproprietary): cefdinir
Active ingredients: Cefdinir monohydrate — 250 mg/5mL
Dosage form: Powder, For suspension
Route: Oral
Labeler: A-S Medication Solutions
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 065332
Marketing start: May 8, 2007
Listing expires: Dec 31, 2027
Other FDA classes: Cephalosporins (Chemical structure)
Identifiers: Product ID 50090-3725_3cc63f9c-2bd7-41d6-a5cd-ceb9be0d6d7bSPL ID 3cc63f9c-2bd7-41d6-a5cd-ceb9be0d6d7bSPL set ID 0eeac6df-bad7-413e-8b41-0660f3a99373RxCUI 476576UNII 6E7SN358SE
Pharmacologic class: Cephalosporin Antibacterial

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N450090372500 followed by a unit qualifier and the quantity

Package 50090-3725-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 20, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir for oral suspension, USP and other antibacterial drugs, cefdinir for oral suspension, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir for oral suspension, USP is indicated for the treatment of patients with mild to moderate infe…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 065332

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 065332
Product	Strength	Form · route	Labeler	Product NDC
Cefdinir	Cefdinir 125 mg/5mL	Powder, For suspensionOral	A-S Medication Solutions	50090-4258
Cefdinir	Cefdinir monohydrate 250 mg/5mL	Powder, For suspensionOral	Proficient Rx LP	63187-616
Cefdinir	Cefdinir monohydrate 125 mg/5mL	Powder, For suspensionOral	NuCare Pharmaceuticals, Inc.	68071-3156
Cefdinir	Cefdinir monohydrate 250 mg/5mL	Powder, For suspensionOral	Preferred Pharmaceuticals Inc.	68788-8655
Cefdinir	Cefdinir monohydrate 125 mg/5mL	Powder, For suspensionOral	Teva Pharmaceuticals USA, Inc.	0093-4136
Cefdinir	Cefdinir monohydrate 250 mg/5mL	Powder, For suspensionOral	Teva Pharmaceuticals USA, Inc.	0093-4137